See more : PT HATTEN BALI Tbk (WINE.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Homology Medicines, Inc. (FIXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Homology Medicines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- EKO International Corp. (EKNL) Income Statement Analysis – Financial Results
- Union Financière de France Banque SA (UFF.PA) Income Statement Analysis – Financial Results
- Mabuchi Motor Co., Ltd. (MBUMY) Income Statement Analysis – Financial Results
- GENPHARMASEC LIMITED (GENPHARMA.BO) Income Statement Analysis – Financial Results
- Advent Technologies Holdings, Inc. (ADNWW) Income Statement Analysis – Financial Results
Homology Medicines, Inc. (FIXX)
About Homology Medicines, Inc.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16M | 3.21M | 33.97M | 2.70M | 1.67M | 3.68M | 0.00 | 0.00 |
| Cost of Revenue | 578.00K | 2.60M | 9.54M | 100.39M | 89.40M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 578.00K | 609.00K | 24.43M | -97.69M | -87.73M | 3.68M | 0.00 | 0.00 |
| Gross Profit Ratio | 50.00% | 18.98% | 71.91% | -3,615.47% | -5,266.03% | 100.00% | 0.00% | 0.00% |
| Research & Development | 62.00M | 98.35M | 93.09M | 100.39M | 89.40M | 47.95M | 21.38M | 5.69M |
| General & Administrative | 31.26M | 38.14M | 36.84M | 32.57M | 22.21M | 17.30M | 8.28M | 4.31M |
| Selling & Marketing | -578.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.68M | 38.14M | 36.84M | 32.57M | 22.21M | 17.30M | 8.28M | 4.31M |
| Other Expenses | 9.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -876.00K | 1.93M |
| Operating Expenses | 92.68M | 136.49M | 129.92M | 132.97M | 111.61M | 65.25M | 29.66M | 10.00M |
| Cost & Expenses | 93.26M | 136.49M | 129.92M | 132.97M | 111.61M | 65.25M | 29.66M | 10.00M |
| Interest Income | 5.58M | 3.23M | 185.00K | 1.57M | 6.03M | 4.35M | 542.64K | 24.20K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 578.00K | -129.96M | 8.35M | 7.97M | 6.32M | 1.29M | 684.21K | 239.80K |
| EBITDA | -91.52M | -133.28M | -87.60M | -122.30M | -103.63M | -60.28M | -28.97M | -9.76M |
| EBITDA Ratio | -7,917.30% | -8,205.64% | -257.86% | -4,526.20% | -6,219.99% | -1,636.13% | 0.00% | 0.00% |
| Operating Income | -92.10M | -133.28M | -95.95M | -130.26M | -109.94M | -61.56M | -29.66M | -10.00M |
| Operating Income Ratio | -7,967.30% | -4,154.64% | -282.44% | -4,820.98% | -6,599.22% | -1,671.12% | 0.00% | 0.00% |
| Total Other Income/Expenses | 14.35M | 134.48M | 185.00K | 1.57M | 6.03M | 4.35M | -333.37K | 1.95M |
| Income Before Tax | -87.08M | 1.20M | -95.76M | -128.69M | -103.92M | -57.22M | -29.99M | -8.05M |
| Income Before Tax Ratio | -7,532.87% | 37.34% | -281.90% | -4,762.92% | -6,237.45% | -1,553.07% | 0.00% | 0.00% |
| Income Tax Expense | 25.88M | 715.00K | -185.00K | -1.57M | -6.03M | 4.35M | -542.64K | -24.20K |
| Net Income | -112.96M | 483.00K | -95.58M | -127.13M | -97.89M | -57.22M | -29.99M | -8.05M |
| Net Income Ratio | -9,771.71% | 15.06% | -281.35% | -4,704.85% | -5,875.69% | -1,553.07% | 0.00% | 0.00% |
| EPS | -351.57 | 1.51 | -311.20 | -498.41 | -418.35 | -360.70 | -159.96 | -77.86 |
| EPS Diluted | -351.57 | 1.51 | -311.20 | -498.41 | -418.35 | -360.70 | -159.96 | -77.86 |
| Weighted Avg Shares Out | 321.30K | 318.89K | 307.13K | 255.06K | 233.99K | 158.62K | 187.49K | 103.35K |
| Weighted Avg Shares Out (Dil) | 321.30K | 318.89K | 307.13K | 255.06K | 233.99K | 158.62K | 187.49K | 103.35K |
Homology Medicines Declares Distribution to Common Stockholders
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
HOMOLOGY MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders
Q32 Bio and Homology Medicines Announce Merger Agreement
Q32 Bio and Homology Medicines Announce Merger Agreement
Homology Medicines Reports Third Quarter 2023 Financial Results
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (NASDAQ: FIXX) and Encourages Long-Term Investors to Contact the Firm - FIXX
Source: https://incomestatements.info
Category: Stock Reports